IKappaB kinase inhibitors (Maxia)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameIKappaB kinase inhibitors (Maxia)
Drug Alias NameMX-20020 seriesMX-6124MX-6106
ClassificationSmall molecules
Mechanisms of ActionNuclear factor NF-kappa-B complex modulatorsAnticancer protein kinase inhibitorsProtein kinases inhibitors
TargetsNuclear factor NF-kappa-B complexProtein kinases
Therapy Area/IndicationsInflammationBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMaxia Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMaxia Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsInflammationBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A